Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uCD7 CART in Relapsed/Refractory CD7+ Hematologic Malignancies
NCT07109518Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uCD7 chimeric antigen receptor T cells in acute myeloid leukemia (AML) and T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-limiting toxicity at 3 months and Number of adverse event of CD7 CART cells treatment at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
uCD7 chimeric antigen receptor T cells
03
Conditions
acute myeloid leukemia (AML)T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on NCT07109518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109518.